Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
Cerevel Therapeutics announced positive Phase 1b trial results for CVL-231, a potential treatment for schizophrenia. Both 30 mg once-daily and 20 mg twice-daily doses significantly improved PANSS total scores by 12.7 and 11.1 points, respectively, compared to placebo (p=0.023 and p=0.047). The trial showed a good safety profile, with adverse events similar to placebo. Cerevel plans to advance CVL-231 to Phase 2 development and explore its potential in dementia-related psychosis. This breakthrough could lead to a new class of antipsychotic medications.
Cerevel Therapeutics announced that the FDA has granted Fast Track designation to CVL-871, a D1/D5 partial agonist, aimed at treating dementia-related apathy. This designation facilitates early communication with the FDA, potentially leading to a faster review process. Dementia-related apathy is a significant issue affecting approximately 50% of dementia patients, leading to decreased quality of life and increased caregiver burden. Cerevel plans to initiate a Phase 2a exploratory trial for CVL-871 soon, with data anticipated in the second half of 2022.
Cerevel Therapeutics, listed on Nasdaq as CERE, announced participation in two key virtual investor conferences in June 2021. The first event is the Jefferies Virtual Healthcare Conference on June 3, featuring a fireside chat at 9:30 a.m. EDT. The second event is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, with a fireside chat scheduled for 11:20 a.m. EDT. Live audio webcasts with CEO Tony Coles will be available on the company’s investor relations website.
Cerevel Therapeutics (CERE) announced a strategic non-dilutive financing of $125 million aimed at supporting its lead asset, tavapadon, currently in Phase 3 trials for Parkinson's disease. The company reported a cash position of $343.3 million as of March 31, 2021, significantly up from $47.5 million year-over-year. Research and development expenses rose to $36.6 million, compared to $27.0 million the previous year, reflecting ongoing clinical trial commitments. Key trial data for CVL-231 in schizophrenia is expected mid-2021, while acute anxiety data for darigabat is anticipated in Q4 2021.
Cerevel Therapeutics (Nasdaq: CERE) announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. Akamine brings extensive experience in healthcare and biopharmaceutical sectors, having previously served at AEON Biopharma, where he managed legal, administrative, and compliance functions. CEO Tony Coles emphasized Akamine's strong legal expertise as vital for the company's growth trajectory in neuroscience therapies. Cerevel is focused on innovative treatments for conditions like Parkinson’s disease and schizophrenia, supported by a diverse pipeline of investigational therapies.
Cerevel Therapeutics (Nasdaq: CERE) will announce its Q1 2021 financial results on May 17, 2021, before market opening. A conference call is scheduled for the same day at 8:00 a.m. EDT, accessible via domestic and international dial-ins. The company's diversified pipeline includes five clinical-stage investigational therapies targeting neuroscience diseases such as Parkinson's and epilepsy. Cerevel aims to advance its research and development while exploring new modalities through collaboration and potential acquisitions.
Cerevel Therapeutics announces the appointment of Abraham N. Ceesay as president, effective May 3, 2021. Ceesay, with nearly two decades of leadership in biopharmaceuticals, previously served as CEO of Tiburio Therapeutics. His role will focus on enhancing Cerevel's commercial capabilities and overseeing corporate strategy and business development. Cerevel aims to tackle neuroscience diseases such as Parkinson’s and epilepsy with a pipeline of five clinical-stage therapies. The leadership change is expected to strengthen the company’s position in the neuroscience sector.
Cerevel Therapeutics has secured up to $125 million in non-dilutive funding from NovaQuest and Bain Capital to finance the Phase 3 development of tavapadon for Parkinson's disease, enabling a planned NDA submission. The funding, received in four installments over four years, will not dilute existing shareholder equity. Cerevel retains significant upside potential from tavapadon sales and holds full worldwide rights. Preliminary data from ongoing TEMPO trials is anticipated in the first half of 2023, extending the company's cash runway into 2024.
Cerevel Therapeutics (Nasdaq: CERE) reported its fourth quarter and full year 2020 results on March 24, 2021. The company ended 2020 with $383.6 million in cash, substantially up from $79.6 million in 2019, thanks to a successful go-public transaction. R&D expenses rose to $103.3 million, driven by advancements in clinical trials for drug candidates like tavapadon and darigabat. Looking ahead, 2021 is positioned as a pivotal year with multiple clinical data readouts anticipated and R&D expenses expected to increase.
Cerevel Therapeutics (Nasdaq: CERE) will have its CEO, Tony Coles, participate in a fireside chat at the Stifel 3rd Annual CNS Day on March 31, 2021, at 9:00 a.m. EDT. Investors can access the live webcast in the investor relations section of the Cerevel website. The company focuses on neuroscience diseases and has a diversified pipeline including five clinical-stage therapies for conditions like schizophrenia and epilepsy. Cerevel is committed to advancing its research and potential collaborations or acquisitions.
FAQ
What is the current stock price of Cerevel Therapeutics Hldng (CERE)?
What is the market cap of Cerevel Therapeutics Hldng (CERE)?
